Home | All trials

[RDF data]
Trial NCT00000392

Resource URI: http://static.linkedct.org/resource/trials/NCT00000392
PropertyValue
linkedct:brief_title Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
linkedct:condition <http://static.linkedct.org/resource/condition/2998>
linkedct:condition <http://static.linkedct.org/resource/condition/5486>
linkedct:criteria Inclusion Criteria: - Patients must have: 1. Cognitive dysfunction on neuropsychological testing. 2. HIV antibody positivity. 3. Expected survival of 6 months. 4. EITHER no use of an antiretroviral within the past 4 weeks OR use of approved regimens of AZT, ddI, or ddC. 5. Medically stable EKG and urinalysis. 6. Given informed, written consent to participate. - Allowed: 1. Inhaled aerosolized pentamidine for Pneumocystis carinii pneumonia prophylaxis, dapsone, cotrimoxazole, topical antifungal agents, nystatin or ketoconazole, acyclovir. 2. Amitriptyline (up to 50 mg/day) or an equivalent dose of another antidepressant for relief of peripheral neuropathy that is expected to remain unchanged throughout the first 6 months of the study. - Abstinence or agree to use barrier methods of birth control / contraception during the study - Negative pregnancy test within 30 days of study entry - Bilirubin <= 3 - CD4 (Must be <= 500 cells/mm3 if patient is without non-cognitive HIV-related symptoms. CD4 count > 500 cells/mm3 allowed if patient has other (non-cognitive) HIV-related symptoms. ( 0 - 100 - 200 - 300 - 400 - 500 - 600 - 700 - 800 plus.) - Creatinine <= 1.5 mg/dl - Granulocytes >= 750 - Hemoglobin > 8 g/dl (No more than two transfusions per month permitted.) - Other Lab Values Prothrombin time > 70 percent of control. - Platelet Count >= 75000 /mm3 - SGOT(AST) < 5 x ULN (ULN = upper limit of normal). Exclusion Criteria: - Patients with the following are excluded: 1. History of mental retardation or learning disability. 2. Evidence of current DSM-III-R Axis I disorder within 3 months prior to study entry or past history of psychotic disorder or bipolar mania. 3. History of neurologic disorder not secondary to HIV infection (e.g., head trauma requiring medical observation or hospitalization, seizure disorder). - Patients with the following symptoms or conditions are excluded: 1. Kaposi's sarcoma or other malignancy likely to require chemotherapy during the first 6 months of the study. 2. Serious underlying medical problems that may complicate interpretation of the treatment results, including unstable diabetes mellitus, severe arteriosclerotic heart disease, uncontrolled hypertension, or hepatic or renal failure. 3. Non-HIV related condition that is likely to interfere with interpretation of neuropsychologic test results. 4. Inability to participate in neuropsychologic testing or unable to comply with intranasal study medication administration. - Excluded within 4 weeks prior to study entry: 1. Antiretrovirals except as allowed in the Patient Inclusion Criteria. 2. Psychoactive agents (e.g., benzodiazepines, antidepressants, antipsychotics, amphetamines) Excluded within 8 weeks prior to study entry: Long-acting psychoactive agents (e.g., Prozac). - Active alcohol abuse in the past 3 months, or abuse judged by the investigators as likely to interfere with the analyses of neuropsychologic function. Abuse of cocaine, marijuana, heroin or other opiates (including methadone), barbiturates, amphetamines or other substances within the past 3 months, judged by the investigators as likely to interfere with the analyses of neuropsychologic tests. - Positive pregnancy test within 30 days of study entry - No abstinence or no agreement to use barrier methods of birth control / contraception during the study
linkedct:download_date Information obtained from ClinicalTrials.gov on December 30, 2009
linkedct:eligibility_gender Both
linkedct:eligibility_maximum_age 60 Years
linkedct:eligibility_minimum_age 18 Years
linkedct:enrollment 0 (xsd:int)
linkedct:firstreceived_date January 17, 2000
linkedct:id NCT00000392
rdfs:label Trial NCT00000392
linkedct:lastchanged_date June 23, 2005
linkedct:lead_sponsor_agency National Institute of Mental Health (NIMH)
linkedct:location <http://static.linkedct.org/resource/location/173658>
linkedct:location <http://static.linkedct.org/resource/location/210066>
linkedct:location <http://static.linkedct.org/resource/location/213376>
linkedct:nct_id NCT00000392
linkedct:number_of_arms 0 (xsd:int)
linkedct:number_of_groups 0 (xsd:int)
linkedct:org_study_id 90 OD-0013
linkedct:overall_status Active, not recruiting
linkedct:oversight <http://static.linkedct.org/resource/oversight/2918>
foaf:page <http://clinicaltrials.gov/show/NCT00000392>
linkedct:phase Phase 2
linkedct:source National Institute of Mental Health (NIMH)
linkedct:study_design Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment
linkedct:study_type Interventional
linkedct:summary To evaluate the chemical efficacy and safety of intranasally administered peptide T on neurocognitive function in HIV seropositive individuals. Previous studies have shown that treatment with peptide T can result in cognitive improvement in HIV-infected patients. Patients are randomized to receive either peptide T or placebo for the first 6 months. All patients then receive open-label peptide T for approximately 6 additional months. Neuropsychologic tests are used to determine drug effects.
rdf:type linkedct:trials
linkedct:verification_date December 1993